Squarepoint
AVIR icon

Squarepoint’s Atea Pharmaceuticals AVIR Stock Holding History

Squarepoint’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Buy
55,098
+35,787
+185% +$164K ﹤0.01% 3720
2025
Q4 		$68.9K Buy
+19,311
New +$61.4K ﹤0.01% 4097
2025
Q2 		– Sell
-15,756
Closed -$47.1K – 4476
2025
Q1 		$47.1K Sell
15,756
-34,994
-69% -$109K ﹤0.01% 4350
2024
Q4 		$170K Buy
50,750
+35,053
+223% +$116K ﹤0.01% 4533
2024
Q3 		$52.6K Buy
15,697
+1,057
+7% +$3.83K ﹤0.01% 3977
2024
Q2 		$48.5K Sell
14,640
-5,513
-27% -$20.6K ﹤0.01% 3908
2024
Q1 		$81.4K Buy
+20,153
New +$78.9K ﹤0.01% 3826
2023
Q4 		– Sell
-41,308
Closed -$124K – 3997
2023
Q3 		$124K Buy
41,308
+22,117
+115% +$75.3K ﹤0.01% 3529
2023
Q2 		$71.8K Sell
19,191
-3,586
-16% -$13.4K ﹤0.01% 3405
2023
Q1 		$76.3K Sell
22,777
-16,237
-42% -$65.9K ﹤0.01% 3016
2022
Q4 		$188K Buy
+39,014
New +$197K ﹤0.01% 2808
2022
Q1 		– Sell
-213,220
Closed -$1.91M – 2806
2021
Q4 		$1.91M Buy
+213,220
New +$3.32M 0.01% 1297

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint's AVIR Position: Q1 2026 in Review

Squarepoint increased its Atea Pharmaceuticals (AVIR) stake by 185% in Q1 2026, buying an estimated $164K and bringing the position to 55,098 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #3720.

Squarepoint first reported a position in AVIR in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.91M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Squarepoint held 55,098 shares of Atea Pharmaceuticals worth $296K as of Q1 2026.
  • Squarepoint bought 35,787 Atea Pharmaceuticals shares in Q1 2026, an estimated $164K.
  • Atea Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3720 holding.
  • Squarepoint first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Squarepoint's Atea Pharmaceuticals position peaked at $1.91M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.